

**Title:** Evidence of Leaky Protection Following COVID-19 Vaccination and SARS-CoV-2 Infection in an Incarcerated Population

**Author List:** Margaret L Lind<sup>1</sup>, Murilo Dorion<sup>1</sup>, Amy J Houde<sup>2</sup>, Mary Lansing<sup>2</sup>, Sarah Lapidus<sup>1</sup>, Russell Thomas<sup>1</sup>, Inci Yildirim<sup>1,3</sup>, Saad B. Omer<sup>1,4,5</sup>, Wade L. Schulz<sup>6,7</sup>, Jason R. Andrews<sup>8</sup>, Matt DT Hitchings<sup>9</sup>, Byron S. Kennedy<sup>2</sup>, Robert P. Richeson<sup>2</sup>, Derek AT Cummings<sup>10,11\*</sup>, Albert I Ko<sup>1,12\*</sup>

**Affiliations:**

1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
2. Connecticut Department of Correction, Wethersfield, CT, USA
3. Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA
4. Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA
5. UT Southwestern, School of Public Health, Dallas, TX, USA
6. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
7. Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
8. Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA
9. Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA
10. Department of Biology, University of Florida, Gainesville, FL, USA
11. Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
12. Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brazil

**Corresponding Authors:**

Margaret L Lind, PhD  
Margaret.Lind@yale.edu  
Department of Epidemiology of Microbial Diseases  
Yale School of Public Health  
60 College St.,  
New Haven, CT 06510

Albert I Ko, MD  
Albert.Ko@yale.edu  
Department of Epidemiology of Microbial Diseases  
Yale School of Public Health  
60 College St.,  
New Haven, CT 06510

1 **Abstract:**

2  
3 Whether SARS-CoV-2 infection and COVID-19 vaccines confer exposure-dependent (“leaky”) protection against infection remains unknown. We examined the effect of prior infection, vaccination, and hybrid immunity on infection risk among residents of Connecticut correctional facilities during periods of predominant Omicron and Delta transmission. Residents with cell, cellblock, and no documented exposure to SARS-CoV-2 infected residents were matched by facility and date. During the Omicron period, prior infection, vaccination, and hybrid immunity reduced the infection risk of residents without a documented exposure (HR: 0.36 [0.25-0.54]; 0.57 [0.42-0.78]; 0.24 [0.15-0.39]; respectively) and with cellblock exposures (0.61 [0.49-0.75]; 0.69 [0.58-0.83]; 0.41 [0.31-0.55]; respectively) but not with cell exposures (0.89 [0.58-1.35]; 0.96 [0.64-1.46]; 0.80 [0.46-1.39]; respectively). Associations were similar during the Delta period and when analyses were restricted to tested residents. Although associations may not have been thoroughly adjusted due to dataset limitations, the findings suggest that prior infection and vaccination may be leaky, highlighting the potential benefits of pairing vaccination with non-pharmaceutical interventions in crowded settings.

17

## 18 Introduction

19 A fundamental question regarding SARS-CoV-2 immunity is whether infection and  
20 vaccination confer all-or-nothing or exposure-dependent (“leaky”) protection against infection.  
21 Despite continued evidence that prior SARS-CoV-2 infections and COVID-19 vaccines provide  
22 protection against infection and COVID-19 related illness, protection is incomplete.<sup>1–8</sup> While key  
23 reasons for imperfect protection include waning protection and variant-specific immune evasion,  
24 differences in the viral dose during an infectious exposure may also contribute.<sup>6,9–16</sup> In alignment  
25 with this hypothesis, the immunity conferred by prior SARS-CoV-2 infection and COVID-19  
26 vaccination have been speculated to be “leaky”, whereby protection reduces infection risk on a  
27 per-exposure basis.<sup>17–20</sup> While there are examples of leaky vaccines for infectious diseases,  
28 including the RTS,S/ASO1 vaccine for malaria<sup>20,21</sup> and attenuated vaccines for Marek’s  
29 disease,<sup>22</sup> empirical evidence for this phenomenon has not been reported for prior SARS-CoV-2  
30 infection and COVID-19 vaccines.

31  
32 The key barrier to interrogating leaky protection in SARS-CoV-2 immunity is the inherent  
33 challenge of measuring viral dose, whether incident or cumulative over time. Investigations thus  
34 rely on evaluating proxies such as proximity and duration of exposure to an infected index case.  
35 Yet, the use of such proxies has been limited by the lack of reliable information at required  
36 scales and by misclassification due to movement and social interactions in real world settings.

37  
38 The controlled social structure of correctional facilities provides an opportunity to address  
39 these limitations and delineate whether prior SARS-CoV-2 infection and COVID-19 vaccination  
40 confer leaky protection. As a result of the defined housing of residents, residents can be  
41 classified as having close exposures (within cell), moderate exposures (within cellblock), or no  
42 documented exposures to a SARS-CoV-2 infected resident on a given day. These exposure  
43 categories can serve as a proxy for exposure risk in a high transmission setting where  
44 movement is restricted between spatial units. Herein, we leveraged the ability to classify  
45 residents by recent SARS-CoV-2 exposures and the high frequency of testing performed by the  
46 Connecticut Department of Correction (DOC) to compare the risk of infection and effects of prior  
47 infection, vaccination, and hybrid immunity (prior infection and vaccination) among residents  
48 with cell, cellblock, and no documented exposures to SARS-CoV-2 infected residents during the  
49 periods of Delta and Omicron predominance in Connecticut, USA.

## 51 Results

### 53 ***COVID-19 prevention and SARS-CoV-2 infections in the correctional system***

54 The Connecticut DOC system is comprised of 13 facilities with a daily census of  
55 approximately 9,300 residents.<sup>23</sup> During the study (June 15, 2021 and May, 10, 2022), a total of  
56 15,444 people spent at least one night housed in a DOC-operated facility, of which, 13,490 and  
57 11,492 were residents during periods, respectively, of predominant Delta variant (June 15 to  
58 December 12, 2021) and Omicron variant (December 13, 2021 to May 10, 2022) transmission in  
59 Connecticut.<sup>24</sup> As of the end of the study, 48% of currently incarcerated residents had  
60 completed their primary vaccine series and 27% had received a booster dose (Figure 1.A).

61  
62 The DOC implemented a SARS-CoV-2 testing program consisting of testing of residents  
63 who were symptomatic, were contacts of confirmed cases, were due in court or had  
64 employment required testing, and residents who were newly incarcerated or transferred  
65 between facilities (rapid antigen testing). In addition, the DOC conducted voluntary, bi-weekly  
66 mass screening of 10% of residents (RT-PCR testing). Contact tracing included testing  
67 residents of (1) the same cell as an infected resident or (2) the same cellblock or facility as an  
68 infected resident if close contact (being within six feet for  $\geq 15$  minutes within a 24-hour period)

69 was reported by the infected resident (see Supplement DOC COVID-19 Testing). In total,  
70 87,884 SARS-CoV-2 tests were performed during the study period, of which 20,794 were RT-  
71 PCRs and 67,090 were rapid antigen tests (Figure 1.B). Contact tracing among residents  
72 without reported symptoms comprised the largest proportion of testing (54%) followed by mass  
73 screening (24%; Figure 1.B). On average, the DOC tested 25% of residents every two weeks  
74 and 65% every three months during the study period.

75  
76 Testing intensified from November 2021 to February 2022 (Figure 1.B) when Delta and  
77 Omicron BA.1 variant transmission contributed to an epidemic wave in Connecticut. During this  
78 period, the average proportion of residents tested in a 14-day period was 33.6% (red line,  
79 Figure 1.C). A total of 5,079 SARS-CoV-2 infections were identified, of which 1,598 and 3,481  
80 occurred during the Delta and Omicron periods, respectively. Among the 5,079 infections, 57%  
81 and 38% were identified through contact tracing among residents without reported symptoms  
82 and testing in the presence of recorded symptoms, respectively (Figure 1.D).

### 83 84 ***Rolling matched cohort of residents exposed to SARS-CoV-2 infection***

85 We conducted a rolling matched cohort study that compared the risk of SARS-CoV-2  
86 infection and effectiveness of prior infection, vaccination, and hybrid immunity among residents  
87 with cell, cellblock, and without documented exposures to an infected case (Supplement Figure  
88 1). A cell exposure event was defined as having  $\geq 1$  cellmate test positive for SARS-CoV-2 in the  
89 absence of cellmates testing positive in the prior 14 days. A cellblock exposure event was  
90 defined as having  $\geq 1$  resident of the same cellblock (but different cell) test positive in the  
91 absence of a cellmate or resident of the cellblock testing positive in the prior 14 days. Events  
92 without documented exposures were defined as days when residents did not have a cell or  
93 cellblock exposure event in the prior 14 days. We prevented the inclusion of multiple events  
94 without documented exposures from the same person during a 14-day period through random  
95 selection. We selected a cohort of events by cluster matching on facility and calendar day and  
96 ascertained infection in the subsequent 14-day period during Delta and Omicron periods.

97  
98 During the Delta period, we identified 290 cell and 5,805 cellblock exposure events  
99 among the 7,389 residents who were incarcerated for  $\geq 14$  days and spent  $\geq 1$  night in a cell with  
100 a roommate (Figure 2.A). Among the 584,629 events without documented exposures, we  
101 randomly selected 37,394 unique events. After matching, we identified a sample of 264 cell  
102 exposure events (258 residents), 5,616 cellblock exposure events (3,745 residents), and 17,024  
103 events without documented exposure (6,073 residents).

104  
105 During the Omicron period, we identified 796 cell and 6,408 cellblock exposure events  
106 and 259,320 events without documented exposures among 6,161 residents who were  
107 incarcerated for  $\geq 14$  days and resided in a cell with a roommate for  $\geq 1$  day (Figure 2.B). We  
108 randomly selected 20,125 of 259,320 events without a documented exposure. Following  
109 matching, we selected 702 cell exposure events (671 residents), 5,980 cellblock exposure  
110 events (4,135 residents), and 13,464 events without documented exposures (5,429 residents).

### 111 112 ***Characteristics of residents with and without exposure to SARS-CoV-2 infections***

113 During the Delta period, events with and without documented exposures occurred  
114 among racially similar residents and residents with similar cell sizes (median: 2 residents).  
115 However, cellblock exposure events occurred more frequently among residents of larger median  
116 cellblock sizes (107.0 residents) than cell exposure events (73.5 residents) or events without  
117 documented exposures (88.0 residents). Cell exposure events occurred more frequently among  
118 unvaccinated residents (58.7%) than cellblock exposure events or events without a documented  
119 exposure (46.3%). Cell exposure events occurred less frequently among people with recorded

120 prior infections (32.2%), vaccination (41.3%), or hybrid immunity (17.1%) than events without  
121 documented exposures (infection, 38.8%; vaccination, 53.7%; hybrid, 25.2%; Table 1). Male  
122 residents were more likely to have had a prior, recorded SARS-CoV-2 infection than female  
123 residents regardless of their SARS-CoV-2 exposure status (Supplement Table 1). Among  
124 residents of the same age, race, room-size, cellblock, and inclusion time, the time since last  
125 prior infection and vaccination did not differ significantly between residents with and without  
126 documented exposures (Supplement Table 2).

127  
128 During the Omicron period, events with and without documented exposures occurred  
129 among racially similar residents and residents with similar cell and cellblock sizes. Cell exposure  
130 events occurred with similar frequency among unvaccinated residents (46.0%) as cellblock  
131 exposure events (43.1%) and events without documented exposures (42.9%). Cell exposure  
132 events occurred less frequently among people with recorded prior infections (36.2%) or hybrid  
133 immunity (23.9%) than cellblock exposure events (prior infection: 43.6%; hybrid immunity:  
134 28.9%) or events without documented exposures (prior infection: 47.0%; hybrid immunity:  
135 30.4%; Table 1). Male residents were more likely to have had a prior, recorded SARS-CoV-2  
136 infection than female residents regardless of their exposure status (Supplement Table 1).  
137 Among residents of the same age, race, room-size, cellblock, and inclusion time, the time since  
138 last prior infection and vaccination did not differ significantly between residents with and without  
139 documented exposures (Supplement Table 2).

#### 140 141 ***High exposure settings in cells and cellblocks impart increased infection risk***

142 During the Delta period, 122 residents tested positive following an event without  
143 documented exposure, 233 residents tested positive following a cellblock exposure event, and  
144 53 residents tested positive following a cell exposure event (Figure 2.A). The hazard of infection  
145 was 2.67 (95% Confidence Interval [CI]: 1.84-3.88) and 9.70 (6.29-14.96) times higher following  
146 cellblock and cell exposure events than events without documented exposure, respectively  
147 (Figure 3). The hazard of symptomatic infection, defined as a positive rapid antigen test  
148 collected from a symptomatic resident, was 2.21 (1.28-3.82) and 7.44 (3.87-14.30) times higher  
149 following cellblock and cell exposure events than events without documented exposure,  
150 respectively (Supplement Figure 2; Unadjusted estimates: Supplement Table 4).

151  
152 We conducted a series of sensitivity analyses to address concerns regarding potential  
153 sources of bias (Supplement: Sensitivity Analyses). Of primary concern is the bias resulting  
154 from unequal testing following events with and without documented exposure (Figure 1.C;  
155 Supplement Figure 4). To examine these biases, we performed sensitivity analyses (1)  
156 restricted to residents who were tested during follow-up and (2) restricted to residents tested  
157 during follow-up for non-symptomatic reasons. Following the restriction to tested residents, the  
158 hazard of infection was 1.89 (1.36-2.64) and 5.23 (3.50-7.82) times higher following cellblock  
159 and cell exposure events than events without documented exposures, respectively (Supplement  
160 Figure 5; Unadjusted estimates: Supplement Table 9). Restricting to tests conducted for non-  
161 symptomatic reasons resulted in the exclusion of an additional 12 facility exposure events and  
162 the point estimates were within 0.01 of the sensitivity analysis restricting to tested residents  
163 (Supplement Figure 7; Unadjusted estimates: Supplement Table 11).

164  
165 Additionally, we did not have access to community infection data and were concerned  
166 about the bias introduced from prior infection misclassification. To reduce this bias, we  
167 conducted a sensitivity analysis limited to people incarcerated since the beginning of our study  
168 (June 15, 2021). The hazard of infection was 3.15 (2.01-4.92) and 12.96 (7.90-21.26) times  
169 higher following cellblock and cell exposure events than events without documented exposure,  
170 respectively (Supplement Figure 9; Unadjusted estimates: Supplement Table 13). Further, since

171 we may have overestimated the effect of facility exposures by including residents who were  
172 exposed to more than one index case on a given day, we conducted a sensitivity analysis  
173 limited to cellblock and cell exposure events with only one index case. To ensure including  
174 already infected residents did not drive our findings, we conducted an analysis restricted to  
175 residents who tested negative in the prior five days. To ensure our exposures were temporally  
176 linked to observed infections, we conducted two sensitivity analyses: one excluding the first 2  
177 days of follow-up, and one limiting follow-up to nine days. We found that cellblock and cell  
178 exposure events were significantly associated with the hazards of infection for each scenario  
179 (Supplement Figures: 11, 13, 14, 16; Unadjusted estimates: Supplement Table 15, 17, 18, 20).

180  
181 During the Omicron period, 167 residents tested positive following an event without  
182 documented exposures, 502 residents tested positive following a cellblock exposure event, and  
183 109 residents tested positive following a cell exposure event (Figure 2.B). The hazard of  
184 infection was 3.34 (2.22-5.00) and 4.73 (3.05-7.36) times higher following cellblock or cell  
185 exposure events than events without documented exposure, respectively (Figure 3). The hazard  
186 of symptomatic infection was 3.82 (2.08-7.00) and 7.00 (3.61-13.58) times higher following  
187 cellblock and cell exposure events than events without documented exposure, respectively  
188 (Supplement Figure 2; Unadjusted estimates: Supplement Table 4).

189  
190 We conducted the same sensitivity analyses as for the Delta period. Following the  
191 restriction to tested residents, the hazard of infection was 2.14 (1.62-2.82) and 2.23 (1.62-3.07)  
192 times higher following cellblock and cell exposure events than events without documented  
193 exposure, respectively (Supplement Figure 5; Unadjusted estimates: Supplement Table 9).  
194 Following the restriction to residents incarcerated since the beginning of the study, the hazard of  
195 infection was 4.40 (2.84-6.82) and 6.17 (3.75-10.14) times higher following cellblock and cell  
196 exposure events than events without documented exposure (Supplement Figure 9; Unadjusted  
197 estimates: Supplement Table 13). Cellblock and cell exposures were found to be significantly  
198 associated with an increased hazard of infection for each additional scenario (Supplement  
199 Figures: 7, 11, 13, 14, 16; Unadjusted estimates: Supplement Tables 11, 15, 17, 18, 20).

### 200 201 ***High exposure setting overcomes the protection afforded by infection, vaccination, and*** 202 ***hybrid immunity***

203 During the Delta period, the effectiveness of prior infection at reducing the hazard of  
204 SARS-CoV-2 infection was highest following events without documented exposure (Hazard  
205 Ratio [HR]: 0.21 [0.11-0.39]) and lowest following cell exposure events (HR: 0.59 [0.30-1.16]).  
206 Vaccine effectiveness was highest following events without documented exposure (HR: 0.32  
207 [0.21-0.49]) and lowest following cell exposure events (HR: 0.74 [0.37-1.48]). The effectiveness  
208 of hybrid immunity was highest following events without documented exposure (HR: 0.05 [0.02-  
209 0.10]) and lowest following cell exposure events (HR: 0.29 [0.07-1.12]). The effectiveness of  
210 prior infection, vaccination, and hybrid immunity was significantly lower following cell exposure  
211 events than following events without documented exposure (P=0.029, 0.033, 0.026,  
212 respectively; Figure 4/Supplement Table 6). The effectiveness of prior infection and vaccination  
213 at reducing the hazard of symptomatic SARS-CoV-2 infection was highest following events  
214 without documented exposure (HR: infection, 0.18 [0.07-0.45], vaccination, 0.21 [0.11-0.41])  
215 and lowest following cell exposure events (HR: infection, 0.42 [0.11-1.60], vaccination, 0.53  
216 [0.17-1.64]). No residents with hybrid immunity had a symptomatic infection following a cell  
217 exposure event (Supplement Figure 3; Unadjusted estimates: Supplement Table 5).

218  
219 We performed sensitivity analyses that paralleled those described above (see  
220 Supplement: Sensitivity Analyses). The effectiveness of prior infection and hybrid immunity was  
221 highest following events without documented exposure and lowest following cell exposure

222 events under all scenarios (Supplement Figures 6, 8, 10, 12, 15, 17; Unadjusted estimates:  
223 Supplement Tables 10, 12, 14, 16, 19, 21). Vaccine effectiveness was highest following events  
224 without documented exposures for all scenarios, except when we limited follow-up to nine days  
225 (Supplement Figure 17; Unadjusted estimates: Supplement Table 21). Under this scenario,  
226 vaccination reduced the hazard of infection by 0.31 (0.19-0.51) times following events without  
227 documented exposure, 0.31 (0.21-0.46) times following cellblock exposure events, and 0.87  
228 (0.45-1.69) times following cell exposure events. When we restricted to residents tested during  
229 follow-up, the effectiveness of prior infection, vaccination, and hybrid immunity was highest  
230 following events without documented exposure (HR: infection, 0.23 [0.12-0.42]; vaccination,  
231 0.34 [0.22-0.52]; hybrid, 0.05 [0.01-0.11]) and lowest following cell exposure events (HR:  
232 infection, 0.50 [0.25-0.98]; vaccination, 0.72 [0.37-1.41]; hybrid, 0.33 [0.12-0.91]; Supplement  
233 Figure 6; Unadjusted estimates: Supplement Table 10). Following the restriction to people  
234 incarcerated since the beginning of the study, the effectiveness of prior infection, vaccination,  
235 and hybrid immunity was highest following events without documented exposure (HR: infection,  
236 0.25 [0.13-0.48]; vaccination, 0.32 [0.19-0.54]; hybrid, 0.07 [0.02-0.18]) and lowest following cell  
237 exposure events (HR: infection, 0.51 [0.25-1.03]; vaccination, 0.77 [0.38-1.58]; hybrid, 0.31  
238 [0.10-0.99]; Supplement Figure 10; Unadjusted estimates: Supplement Table 14).

239  
240 During the Omicron period, the effectiveness of prior infection was highest following  
241 events without documented exposure (HR: 0.36 [0.25-0.54]) and lowest following cell exposure  
242 events (HR: 0.89 [0.58-1.35]). Vaccine effectiveness was highest following events without  
243 documented exposure (HR: 0.57 [0.42-0.78]) and lowest following cell exposure events (HR:  
244 0.96 [0.64-1.46]). The effectiveness of hybrid immunity was highest following events without  
245 documented exposure (HR: 0.24 [0.15-0.39]) and lowest following cell exposure events (HR:  
246 0.80 [0.46-1.39]). The effectiveness of prior infection, vaccination, and hybrid immunity was  
247 significantly lower following cell exposure events than events without documented exposure  
248 ( $P=0.002$ ,  $0.041$ , and  $0.001$ , respectively; Figure 4/Supplement Table 6). The effectiveness of  
249 prior infection, vaccination, and hybrid immunity at reducing the hazard of symptomatic SARS-  
250 CoV-2 infection was highest following events without documented exposure (HR: infection, 0.35  
251 [0.21-0.59]; vaccination, 0.33 [0.21-0.53]; hybrid, 0.13 [0.06-0.28]) and lowest following cell  
252 exposure events (HR: infection, 0.77 [0.45-1.31]; vaccination, 0.62 [0.35-1.10]; hybrid, 0.53  
253 [0.26-1.11]; Supplement Figure 3; Unadjusted estimates: Supplement Table 5).

254  
255 Following the restriction to residents tested during follow-up, the effectiveness of prior  
256 infection, vaccination, and hybrid immunity was highest following events without documented  
257 exposures (HR: infection, 0.44 [0.30-0.63]; vaccination, 0.49 [0.36-0.68]; hybrid 0.32 [0.19-0.53])  
258 and lowest following cell exposure events (HR: infection, 0.69 [0.47-1.02]; vaccination, 0.81  
259 [0.53-1.22]; hybrid, 0.67 [0.44-1.02]; Supplement Figure 6; Unadjusted estimates: Supplement  
260 Table 10). Following the restriction to people incarcerated since the study began, the  
261 effectiveness of prior infection, vaccination, and hybrid immunity was highest following events  
262 without documented exposures (HR: infection, 0.38 [0.24-0.58]; vaccination, 0.61 [0.43-0.86];  
263 hybrid, 0.23 [0.14-0.38]) and lowest following cell exposure events (HR: infection, 0.88 [0.56-  
264 1.37]; vaccination, 0.79 [0.49-1.28]; hybrid, 0.64 [0.39-1.05]; Supplement Figure 10; Unadjusted  
265 estimates: Supplement Table 14). The effectiveness of prior infection, vaccination, and hybrid  
266 immunity was highest following events without documented exposures and lowest following cell  
267 exposure events for each additional sensitivity analysis (Supplement Figures 8, 12, 15, 17;  
268 Unadjusted estimates: Supplement Tables 12, 16, 19, 21).

## 269 ***SARS-CoV-2 exposure specific effects of prior infection and vaccination on*** 270 ***Infectiousness*** 271

272 As a secondary analysis, we hypothesized that the prior infection and vaccination status  
273 of the index cases may influence transmission. We examined this by restricting our sample to  
274 cellblock and cell exposure events and comparing the hazards of infection when the index case  
275 had and did not have the immunizing event of interest. During the Delta period, the prior  
276 infection history of the index case was associated with a non-significantly higher hazard of  
277 SARS-CoV-2 transmission following cellblock exposure events (HR: 1.96 [0.93-4.12]) and a  
278 non-significantly lower hazard following cell exposure events (HR: 0.91 [95 CI: 0.20-4.18]). The  
279 vaccination status of the index case was associated with a non-significantly lower hazard of  
280 SARS-CoV-2 transmission among cellblock exposure events (HR: 0.75 [0.18-3.12]) and cell  
281 exposure events (HR: 0.71 [0.26-1.93]; Figure 5).

282  
283 During the Omicron period, the prior infection status of the index case was associated  
284 with a non-significantly lower hazard of SARS-CoV-2 transmission following cellblock exposure  
285 events (HR: 0.52 [0.27-1.03]) and cell exposure events (HR: 0.72 [95 CI: 0.25-2.03]). The  
286 vaccination history of the index case was associated with a non-significantly lower hazard of  
287 SARS-CoV-2 transmission among cellblock exposure events (HR: 0.55 [0.24-1.24]) and cell  
288 exposure events (HR: 0.52 [0.20-1.36]; Figure 5).

## 289 Discussion

290 Leveraging the controlled social structure and detailed epidemiological data of correctional  
291 facilities, we found that residents with close (cell) exposures and moderate (cellblock)  
292 exposures to SARS-CoV-2 infected residents had a significantly higher risk of becoming  
293 infected with SARS-CoV-2 than residents without a documented exposure during Delta and  
294 Omicron periods. Further, we found that prior SARS-CoV-2 infection, COVID-19 vaccination,  
295 and hybrid immunity (prior infection and vaccination) significantly reduced the risk of infection  
296 among residents with cellblock exposures and without documented exposures, but not residents  
297 with cell exposures during both periods. Finally, we found that the vaccination status of the  
298 index case was associated with a non-significant reduction in the risk of secondary SARS-CoV-  
299 2 cases following cell and cellblock exposures during Delta and Omicron periods.

300  
301 Our findings indicate that exposure to an infected resident in a cell or cellblock significantly  
302 increased the risk of becoming infected with SARS-CoV-2 and supports the benefit of contact  
303 tracing within the cell and cellblock of infected residents. These findings held irrespective of the  
304 period when differing variants were circulating. However, the magnitude of the cell exposure  
305 effect was smaller during the Omicron period than the Delta period, potentially due to the  
306 increased transmissibility of the Omicron variant.<sup>25-27</sup> Despite the observed decline in effect  
307 size, cellblock or cell exposures increased the hazard of infection by 3.3 and 4.7 times during  
308 the Omicron period, respectively. These findings speak to the continued need for contact tracing  
309 within correctional facilities and other high-density settings, including nursing homes, and  
310 suggest that contact tracing should not be limited to residents of the same cell but include  
311 residents that interact during recreation and meals, as is the case among residents of the same  
312 cellblock within Connecticut DOC run facilities.

313  
314 During both the Delta and Omicron periods, we found that neither prior infection, nor  
315 vaccination, nor hybrid immunity provided significant levels of protection against SARS-CoV-2  
316 infection following cell exposure events and that the levels of protection were significantly  
317 smaller following cell exposure events than following events without documented exposures.  
318 Further, despite having a limited sample during the period of Delta predominance, we observed  
319 similar gradients in the level of protection offered by prior infection, vaccination, and hybrid  
320 immunity against symptomatic infection. These findings provide empirical evidence that, while  
321 accounting for factors thought to be associated with vaccine acceptance and infection, the  
322



323 protection offered by prior infection, vaccination, and hybrid immunity, appears to be leaky. They  
324 suggest that there may be an additional mechanism, based on the intensity of the infectious  
325 exposure, which may explain observed, partial levels of immunity conferred by infection and  
326 vaccination, in addition to factors such as variant-specific immune escape, waning immunity and  
327 reduced effectiveness in specific subpopulations, such as older people.<sup>28-30</sup>  
328

329 Beyond providing an evidence base for the mechanism by which prior SARS-CoV-2  
330 infections and COVID-19 vaccines confer immunity, these findings have broad implications on  
331 SARS-CoV-2 transmission modeling, vaccine effectiveness analyses, and prevention strategy  
332 development. Though most SARS-CoV-2 transmission models likely incorporate a simplifying  
333 assumption that the vaccines provide leaky protection,<sup>31,32</sup> the validity of this assumption has not  
334 been previously documented with empirical data and model parameterization based  
335 examinations were found to be inconclusive.<sup>31</sup> Thus, our findings provide evidence that this  
336 assumption may be valid. They also indicate that when estimating future disease burdens under  
337 scenarios of defined exposures, modelers may need to account for the reduced effectiveness of  
338 prior infections and vaccinations among modeled participants with prolonged, close  
339 exposures.<sup>31,32</sup> Furthermore, theoretical studies have demonstrated that the efficacy of leaky  
340 vaccines is underestimated by common study designs, which may contribute to variation in  
341 observed vaccine effectiveness across settings.<sup>17,33</sup>  
342

343 These findings also suggest the benefit of layered interventions in general, and particularly  
344 within densely packed social settings. In the presence of leaky vaccines, non-pharmaceutical  
345 interventions have been proposed in tandem with vaccination in order to reduce exposure and  
346 mitigate infection spread.<sup>34</sup> Such interventions may include social distancing, quarantine and  
347 isolation, masking, and improved ventilation and airflow.<sup>35,36</sup> While our findings are obtained  
348 from the investigation of a correctional facility system, in the presence of a leaky vaccine,  
349 layered interventions may afford a benefit in other congregate settings and community settings  
350 where prolonged, close contact with infected people may occur, such as mass gatherings.  
351

352 If the protection offered by vaccination is indeed leaky, the increased transmissibility of the  
353 Omicron variant may have contributed to the well documented decline in the effectiveness of  
354 vaccination during periods of Omicron predominance.<sup>26,27,37</sup> In alignment with prior studies and  
355 this speculation, we observed lower levels of protection during the Omicron period. Though this  
356 decline has been primarily attributed to variant specific immune escape due to the large number  
357 of mutations present in the spike protein,<sup>37-39</sup> the high transmissibility of the Omicron variant  
358 may have resulted in high enough exposure levels (pathogen pressure) in the community to  
359 enhance the effects of leaky protection in populations that experienced prior SARS-CoV-2  
360 infection and/or vaccination. This speculation invokes the question of whether layered  
361 interventions would provide increased benefit in general settings, not just within densely packed  
362 settings, when highly transmissible variants are circulating.  
363

364 We found that hybrid immunity offered the highest level of protection, followed by prior  
365 infection. While this finding aligns with prior studies,<sup>40-42</sup> the observed differences in the level of  
366 protection may reflect the recency of prior infections compared to vaccination (due to an artificial  
367 truncation of the time since infection resulting from the absence of community infection data).  
368 However, the absence of community infection data results in prior infection misclassification  
369 and, alternatively, may have resulted in conservative effectiveness estimates for prior infection.  
370 To examine the impact of these missing data, we conducted a sensitivity analysis limited to  
371 residents incarcerated since June 15, 2021 (study beginning). Relative to the primary analysis,  
372 we did not observe a specific directional shift in the effectiveness estimates, and we observed a  
373 similar gradient in the levels of protection by facility exposure. Though, data limitations

374 prevented us from performing this analysis among people incarcerated since the beginning of  
375 the pandemic, infection-induced seroprevalence estimates from Connecticut suggest that only a  
376 small proportion of the population had been infected as of July 2021 (4.7-19.7%) and the  
377 residual bias is likely limited.<sup>43,44</sup>

378  
379 Our effect estimates on infectiousness during the Omicron period are in alignment with a  
380 prior study by Tan et al.<sup>45</sup> This study conducted in California correctional facilities, found that the  
381 prior infection and vaccination status of an index case reduced the risk of transmission by 40%  
382 (20-55%) and 22% (6-36%), respectively. Similarly, we found that the risk of transmission  
383 following a cell exposure was 0.72 (0.25-2.03) times lower among infected residents with a prior  
384 infection and 0.52 (0.2-1.36) times lower among infected residents with a history of vaccination  
385 than residents without a prior infection or history of vaccination. Though our precision prevents  
386 us from making broad conclusions from these findings, they support the findings of Tan et al.<sup>45</sup>

387  
388 We acknowledge that our study was subject to several limitations. A key potential limitation  
389 stems from testing related differences following events with and without documented exposures.  
390 Though the Connecticut DOC has, and continues to, conduct intensive COVID-19 testing,  
391 testing is more common among residents with an infected cellmate than residents without a  
392 documented exposure (Figure 1.C) and may result in an overestimation of the effect of cell or  
393 cellblock exposures. While we did observe an attenuation towards the null following the  
394 restriction to people who were tested during follow-up, this restriction did not remove the  
395 observed gradient in the levels of protection conferred by prior infection, vaccination, or hybrid  
396 immunity by facility exposure. In addition to testing frequency, we were concerned that  
397 differences in the proportion of tests conducted as a result of symptoms may have introduced  
398 bias into our analysis (Supplement Figure 4). However, very few tests were performed for  
399 symptomatic reasons and we continued to find the levels of protection to be highest following  
400 events without documented exposures and lowest following cell exposure events.

401  
402 Another potential source of testing related bias stems from the contact tracing protocol.  
403 During the study period, the contact tracing protocol remained consistent and followed the  
404 recommendations of the CDC (see Supplement DOC COVID-19 Testing).<sup>46</sup> The protocol stated  
405 that close contacts should be tested five days after contact, however, variation in the exact day  
406 of testing was probable. Because rapid antigen tests (the test used for contact tracing) are  
407 highly sensitive to the viral load, residents tested too soon or long after a contact may have a  
408 false negative test, especially if they have a history of prior infection or vaccination (which  
409 reduces the viral load).<sup>47</sup> If variation in the time between contact and testing existed between  
410 events without documented exposure, cellblock exposure events, and cell exposure events,  
411 upward or downward bias may have been introduced. Testing prioritization is another potential  
412 source of bias from contact tracing. However, due to the testing capacity, contact tracing was  
413 performed among symptomatic and asymptomatic residents with or without history of prior  
414 infections or vaccination and no prioritization was required.

415  
416 Our analysis was conducted in a single DOC system and the findings may not be  
417 generalizable to all correctional facility settings. Further, we did not have testing or infection data  
418 for staff, nor did we have comorbidity and masking data for residents and symptom data for RT-  
419 PCR tests. The absence of comorbidity data may result in biased estimates of effectiveness as  
420 residents with comorbidities are more likely to become vaccinated and may be more or less  
421 likely to become infected with SARS-CoV-2, depending on differential behaviors. However,  
422 through adjusting for age and race, we may have accounted for a part of the confounding effect  
423 of comorbidities. Due to the absence of symptom data for RT-PCRs, we defined symptomatic  
424 infection as a symptomatic rapid antigen test, thus assuming RT-PCR detected infections were

425 asymptomatic. Data limitations prevented us from examining the leakiness of immunity-  
426 conferring events against severe outcomes and future analyses with complete symptomatic and  
427 severe outcomes data should examine leakiness relative to these outcomes.

428  
429 Due to sample limitations, we were unable to stratify vaccination and prior infection status by  
430 time since vaccination. However, we found no significant difference in the time since prior  
431 infection or vaccination between residents with events with and without documented exposures.  
432 Behavioral differences between people with prior infections or who have been vaccinated may  
433 differ from people without a prior infection or vaccination. While this may have led to either an  
434 over or under estimation of the effect of cell or cellblock exposures, it should not have driven our  
435 findings suggesting leakiness. Finally, while we conducted numerous sensitivity analyses to  
436 examine the robustness of our findings, we were unable to account for all potential sources of  
437 bias at the same time and residual bias may be present within our findings.

438  
439 This study provides empiric evidence that COVID-19 vaccination and prior infection confer  
440 exposure dependent (“leaky”) protection against SARS-CoV-2 infections. The findings support  
441 the use of leaky vaccine parameters in SARS-CoV-2 transmission modeling and indicate the  
442 need for modelers to account for the reduced protection conferred by prior infection and  
443 vaccinations among people with prolonged, close exposures. Further, our findings suggest the  
444 need for layered interventions to mitigate SARS-CoV-2 spread, especially within dense settings,  
445 such as congregate settings, and in settings where prolonged contact is likely, such as  
446 households with infected people.

## 447 **Methods**

### 448 ***Population and Data***

449  
450 We conducted a rolling matched cohort analysis among residents of Connecticut DOC  
451 facilities who were incarcerated between June 15, 2021, when Delta became the predominant  
452 variant in Connecticut according to sequenced clinical samples, and May 10, 2022.<sup>24</sup> Resident  
453 demographic (age, race, gender), housing (daily facility, cellblock [block of cells or dorm], cell or  
454 dorm, and bunk), and COVID-19 testing, and vaccination data were extracted from DOC  
455 maintained databases containing data collected as part of routine SARS-CoV-2 surveillance.  
456 Testing records included all rapid antigen (primarily BinaxNOW) and RT-PCR (primarily  
457 analyzed by Quest) tests administered within a DOC operated facility since the beginning of the  
458 pandemic. We excluded residents who never spent a night in a cell with at least one cellmate,  
459 spent less than 14 days incarcerated, or resided exclusively within a restricted housing  
460 cellblock.

461  
462  
463 The research was performed by researchers at the Connecticut Department of  
464 Correction and Yale University (located within the state of Connecticut). All roles and  
465 responsibilities were determined by the collaborating researchers ahead of analysis and the  
466 questions raised were done so collectively. The study was determined to be a public health  
467 surveillance activity by the Yale University Institutional Review Board and exempt from review  
468 (ID: 2000031675). The study results do not stigmatize, incriminate, or discriminate the  
469 participants. Our citation list includes research previously published by this collaborative group  
470 regarding testing policies within the CT DOC and seroprevalence studies from CT (not from this  
471 group).

### 472 ***Department of Correction COVID-19 Protocols***

473  
474 Since the introduction of COVID-19 in the winter of 2019-2020, the Connecticut DOC  
475 has implemented numerous COVID-19 prevention strategies including testing (rapid antigen

476 and RT-PCR), masking, isolation/quarantine, and vaccination. As part of their COVID-19  
477 mitigation strategy, the DOC restricted the interaction of residents during meal and recreation  
478 time to residents of the same cellblock. Thus, during the study period, residents of the same  
479 cellblock interacted with other residents of their cellblock during meal and recreation times but,  
480 unless their employment required them to move throughout the facility, the residents did not  
481 interact with residents of different cellblocks. However, DOC staff continued to move throughout  
482 the facilities and were placed in different cellblocks on different days.

483  
484 Masks are required for all residents while outside of their cell or, if residing in a dorm,  
485 moving around their dorm. This is analogous to a non-incarcerated person wearing a mask  
486 while socializing in public but not having to wear a mask within their home. Testing with RT-  
487 PCRs was and continues to be conducted primarily for mass testing. Testing with rapid antigen  
488 test was and continues to be conducted for five primary reasons: intakes/transfers,  
489 symptomatic, employment, and contact tracing.<sup>48,49</sup> Among residents of cells, contact tracing  
490 included testing all residents of the same cell as the infected resident and residents of the same  
491 cellblock or facility but only if close contact was reported by the infected resident. Close contact  
492 was defined in accordance with the CDC definition (being within six feet for at least 15 minutes  
493 within a 24-hour period).<sup>46</sup> Resident testing as part of mass screening is considered optional but  
494 regular testing is required for many within facility jobs as well as some community facing jobs.  
495 The specific testing requirements vary by position. Residents who test positive for SARS-CoV-2  
496 are moved to isolation the day they test positive. For details on testing see Supplement: DOC  
497 COVID-19 Testing.

498  
499 A detailed description of the vaccination program can be found elsewhere.<sup>49,50</sup> Briefly,  
500 the DOC began their COVID-19 vaccination program on February 2<sup>nd</sup>, 2021 and provided  
501 vaccines to residents who qualified for vaccination according to state-defined eligibility and were  
502 not actively infected. Residents who were partially vaccinated were offered second or  
503 subsequent doses of the corresponding vaccine. Vaccinations received prior to incarceration  
504 were verified using CT WiZ, Connecticut's COVID-19 vaccine registry.<sup>50</sup>

### 506 ***Sample, Type of SARS-CoV-2 Exposure, Follow-up and Matching***

507 For each resident, we identified the days they were housed in a cell. We excluded the  
508 first 14 days a person was in the study along with days a resident was housed in a restricted  
509 housing cellblock, had an undefined housing location, or did not have at least one roommate.  
510 Additionally, to prevent the inclusion of the same infection more than once, we excluded  
511 resident days in the 90 days following a positive SARS-CoV-2 infection.

512  
513 On each included day, residents were classified as having one of three facility structure  
514 defined SARS-CoV-2 exposure event types: cell exposure event, cellblock exposure event, or  
515 events without documented exposure. We classified a resident as having a cell exposure event  
516 if at least one of their cellmates tested positive for SARS-CoV-2, a cellblock exposure event if at  
517 least one resident of the same cellblock but different cell tested positive for SARS-CoV-2, or an  
518 event without documented exposure if no one in their cellblock tested positive for SARS-CoV-2  
519 (Supplement Figure 1). We excluded cell exposure events that occurred within 14 days of a  
520 prior cell exposure event and cellblock exposure events and events without documented  
521 exposures that occurred within 14 days of a prior cellblock or cell exposure event. Further, to  
522 remove the risk of including multiple events without documented exposures from the same  
523 resident during a 14-day period, we randomized the sample of residents with events without  
524 documented exposures and dropped all days for each person within 14 days of the selected  
525 date. Following this exclusion, we cluster matched the cell exposure events, cellblock exposure  
526 events and events without documented exposures on facility (exact) and calendar date (+/- 7

527 days). This ensured that each exposure group was observed at the same time and in the same  
528 facility.  
529

530 Residents were defined as becoming infected with SARS-CoV-2 if they tested positive  
531 during the 14 days following inclusion.<sup>45</sup> We censored resident time on the date of release or  
532 death or when a resident became exposed at a more proximal level (ex. resident with a  
533 cellblock exposure was exposed within their cell). This sampling schematic allowed for residents  
534 to be included in the analysis multiple times for the same or different facility exposure statuses.  
535 The sample was then stratified by variant predominance within Connecticut (Delta: June 15,  
536 2021, through December 12, 2021; Omicron: December 13, 2021, through the end of the study  
537 [May 10, 2022]).<sup>24</sup> We stratified this analysis by variant predominance due to differences in the  
538 transmissibility of the variants and the levels of protection offered by prior infections and  
539 vaccinations against the variants.<sup>15,26,38</sup>  
540

#### 541 ***Prior Infection, Vaccination and Hybrid Immunity Status***

542 We identified the prior infection, vaccination, and hybrid immunity status of residents with  
543 cell exposure events, cellblock exposure events, and events without documented exposure.  
544 Additionally, we identified the prior infection, vaccination, and hybrid immunity status of the  
545 index cases (infected residents that resulted in all cell and cellblock exposures). We classified a  
546 person as being vaccinated if they had received at least one COVID-19 vaccine dose,  
547 regardless of the brand or time since the dose was administered. We defined a prior infection as  
548 a positive, recorded SARS-CoV-2 rapid antigen or RT-PCR test collected in a DOC facility at  
549 least 90 days prior to the date of inclusion. Hybrid immunity was defined as a person having  
550 received at least one vaccine dose and having had at least one prior infection as of the date of  
551 inclusion.  
552

#### 553 ***Statistical Analysis***

554 We visually summarized the vaccine coverage, number of COVID-19 tests and number  
555 of SARS-CoV-2 infections recorded among DOC residents during the study period. We  
556 summarized the resident characteristics of cell exposure events, cellblock exposure events, and  
557 events without documented exposures using medians, first and third quartiles, counts and  
558 percentages. Resident gender is evaluated at intake by correctional officers and designated  
559 based on genitalia (observed during intake strip search) and governmental documents  
560 (passport, driver's license, and birth certificate). We compared the time since last prior infection  
561 and vaccine dose using linear models adjusted for age, race, time of inclusion, room size, and  
562 cellblock (mirroring the adjustment factors included in the primary analyses, see Facility  
563 Exposure Specific Effects of Prior Infection, Vaccination, and Hybrid Immunity on Susceptibility).  
564 Data cleaning, management, and analyses were conducted in R version 4.2.1.  
565

#### 566 ***Association Between Facility Exposure and SARS-CoV-2 Infection Risk***

567 We estimated the association between known SARS-CoV-2 exposure and SARS-CoV-2  
568 infection risk using a facility stratified Cox Proportional Hazards model with an outcome of test  
569 positive SARS-CoV-2 infection, a primary exposure of type of facility exposure (cell exposure  
570 events, cellblock exposure events, or events without documented exposure). Further, to account  
571 for the correlation of events among people residing within the same cellblock, we estimated  
572 confidence intervals using robust standard errors. The model was adjusted for the following a  
573 priori selected potential confounders (Supplement Figure 18): calendar time (continuous), age  
574 (continuous), self-identified race (non-Hispanic Black, non-Hispanic White, Other), and room  
575 and cellblock size (continuous). Continuous variables were modeled flexibly using natural  
576 splines. Though gender is a potential confounder, facilities contain residents of only a single

577 gender and all contrast was eliminated by facility stratification. Significance was defined with an  
578 alpha of 0.05 and determined using two-sided z-tests.

579  
580 *Facility Exposure Specific Effects of Prior Infection, Vaccination, and Hybrid Immunity on*  
581 *Susceptibility*

582 We estimated the association between prior infection and infection risk using a cellblock  
583 stratified Cox Proportional Hazards model with robust standard errors, an outcome of SARS-  
584 CoV-2 infection, a primary exposure of prior infection history, and an interaction term between  
585 facility exposure type and prior infection history. The model was adjusted for the calendar time  
586 (continuous), age (continuous), staff assigned race, room size (continuous), and the vaccination  
587 history of the susceptible resident. The effect of vaccination was examined using the same  
588 model but with an exposure of vaccination instead of prior infection and an adjustment factor of  
589 prior infection. We estimated the effect of hybrid immunity using the same model but with an  
590 exposure of hybrid immunity. This analysis was restricted to residents with either hybrid  
591 immunity or no history of prior infection or vaccination. We tested if the hazard ratios of cell and  
592 cellblock exposure events were significantly different than the hazard ratio for events without  
593 documented exposures using two-sided z-tests and defined significance with an alpha of 0.05.  
594 As a secondary analysis, we estimated the effect of prior infection, vaccination, and hybrid  
595 immunity on the hazard of symptomatic infection. Due to an absence of symptomatic data for  
596 RT-PCR tests, we defined symptomatic infection as a positive rapid antigen test collected from  
597 a symptomatic resident. We used the same models for these analyses as we did for the  
598 infection outcome analyses.

599  
600 *Facility Exposure Specific Effects of Prior Infection and Vaccination on Infectiousness*

601 As a secondary analysis, we were interested in evaluating the impact the index cases'  
602 history of prior infection and vaccination had on the risk of SARS-CoV-2 infection among  
603 residents with cellblock and cell exposure events. For this analysis, we restricted our sample to  
604 residents with facility exposures. If residents were exposed to multiple index cases on the same  
605 day, we restricted to residents who were exposed to index cases with the same prior infection  
606 and vaccination histories. We estimated the effect of prior infection on infectiousness using a  
607 cellblock stratified Cox Proportional Hazards model with robust standard errors. The model had  
608 an outcome of SARS-CoV-2 infection, an exposure of the index case's prior infection history,  
609 and an interaction term between facility exposure type and the index case's prior infection  
610 history. The model was adjusted for the same factors as the susceptibility analysis model and  
611 the vaccination history of the index case. The effect of vaccination was examined using the  
612 same model but with a primary exposure of the index case's vaccination history instead of prior  
613 infection history.

614  
615 **Sensitivity Analyses**

616 To test the robustness of our findings to alternative study design, data cleaning, and  
617 modeling assumptions, we conducted multiple sensitivity analyses (Supplement: Sensitivity  
618 Analyses). Of particular concern was biases due to differences in testing frequency or reasons  
619 for testing among residents with and without cell or cellblock exposures. To examine the impact  
620 of potential testing bias, we conducted two sensitivity analyses. First, we restricted to residents  
621 tested during follow-up. Second, because symptoms are associated with the level of protection  
622 conferred by prior infections and vaccinations, we performed an additional analysis which  
623 excluded residents tested due to symptoms (reason for testing listed as symptomatic).

624  
625 In addition to concerns around testing related biases, we were concerned that the  
626 absence of community infection data may have resulted in biased effectiveness estimates for  
627 prior infections. We examined the impact of this missing data by limiting our sample to people

628 incarcerated since the beginning of the study (June 15, 2021). Additionally, we were concerned  
629 that we may have overestimated the association between documented SARS-CoV-2 exposure  
630 and infection risk by including residents' exposure to multiple infected residents in their cell or  
631 cellblock on the same day. To examine this, we conducted a sensitivity analysis restricted to cell  
632 and cellblock exposure events where only one index case was observed. Further, to ensure that  
633 our decision to include residents without recent negative tests did not drive our findings, we  
634 conducted a sensitivity analysis restricted to residents who tested negative in the prior five days.  
635 Additionally, we wanted to ensure our exposures were temporally linked to observed infections.  
636 To do so, we conducted two sensitivity analyses: one excluding the first 2 days of follow-up, and  
637 one limiting follow-up to nine days. For a detailed description of sensitivity analyses performed  
638 see Supplement: Sensitivity Analyses.  
639  
640

641 **Data Availability:** The data used in this study belongs to the Connecticut Department of  
642 Correction and cannot be shared publicly because of the presence of potentially identifiable  
643 health and resident information. Qualified researchers may request for de-identified, patient  
644 level data by contacting the corresponding author with a detailed description of the research  
645 question and setting up a data use agreement with the Connecticut Department of Correction.  
646

647 **Code Availability:** Code generated to conduct the statistical analyses is available in the  
648 following repository: [https://github.com/lindm89/CT\\_DOC\\_Dose\\_Effect\\_Vax.git](https://github.com/lindm89/CT_DOC_Dose_Effect_Vax.git).<sup>51</sup>



## References

1. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
2. WHO. *Vaccine efficacy, effectiveness and protection*. <https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection> (2021).
3. Thomas, S. J. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N. Engl. J. Med.* **385**, 1761–1773 (2021).
4. Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N. Engl. J. Med.* **383**, 2439–2450 (2020).
5. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med.* **384**, 403–416 (2021).
6. Gazit, S. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **75**, e545–e551 (2022).
7. Tillett, R. L. *et al.* Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect. Dis.* **21**, 52–58 (2021).
8. Sotoodeh Ghorbani, S. *et al.* Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis. *J. Med. Virol.* **94**, 44–53 (2022).

9. Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R. & Ioannidis, J. P. A. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. *Environ. Res.* **209**, 112911 (2022).
10. Lind, M. L. *et al.* Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity to decreasing COVID-19 vaccine effectiveness during alpha and delta variant waves. 2022.08.25.22278443 Preprint at <https://doi.org/10.1101/2022.08.25.22278443> (2022).
11. Grewal, R. *et al.* Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada. *J. Infect. Dis.* jiac468 (2022) doi:10.1093/infdis/jiac468.
12. Andrews, N. *et al.* Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. *N. Engl. J. Med.* **386**, 340–350 (2022).
13. Milne, G. *et al.* Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? *Lancet Respir. Med.* **9**, 1450–1466 (2021).
14. CDC. *Rates of COVID-19 Cases and Deaths by Vaccination Status.* <https://covid.cdc.gov/covid-data-tracker> (2022).
15. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N. Engl. J. Med.* **386**, 1532–1546 (2022).
16. Hall, V. *et al.* Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. *N. Engl. J. Med.* **386**, 1207–1220 (2022).

17. Kahn, R., Schrag, S. J., Verani, J. R. & Lipsitch, M. Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. *Am. J. Epidemiol.* **191**, 800–811 (2022).
18. Edlefsen, P. T. Leaky Vaccines Protect Highly Exposed Recipients at a Lower Rate: Implications for Vaccine Efficacy Estimation and Sieve Analysis. *Comput. Math. Methods Med.* **2014**, e813789 (2014).
19. Langwig, K. E. *et al.* Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose. *Sci. Rep.* **9**, 3203 (2019).
20. Smith, P. G., Rodrigues, L. C. & Fine, P. E. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. *Int. J. Epidemiol.* **13**, 87–93 (1984).
21. White, M. T., Griffin, J. T., Drakeley, C. J. & Ghani, A. C. Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. *Malar. J.* **9**, 82 (2010).
22. Read, A. F. *et al.* Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens. *PLOS Biol.* **13**, e1002198 (2015).
23. Connecticut Department of Correction. Correctional Facility Daily Population Count | Connecticut Data. <https://data.ct.gov/Public-Safety/Correctional-Facility-Daily-Population-Count/tghy-ygnr> (2023).
24. Grubaugh, N. D. & Pham, K. *Yale SARS-CoV-2 Genomic Surveillance Initiative*. <https://kphamyale.shinyapps.io/covidtrackerct/> (2022).

25. CDC. *Potential Rapid Increase of Omicron Variant Infections in the United States*.  
<https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical-modeling-outbreak.html> (2021).
26. Bálint, G., Vörös-Horváth, B. & Széchenyi, A. Omicron: increased transmissibility and decreased pathogenicity. *Signal Transduct. Target. Ther.* **7**, 1–3 (2022).
27. Mohsin, M. & Mahmud, S. Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity. *Medicine (Baltimore)* **101**, e29165 (2022).
28. Cerqueira-Silva, T. *et al.* Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. *Lancet Reg. Health – Am.* **6**, (2022).
29. Ranzani, O. T. *et al.* Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. *BMJ* **374**, n2015 (2021).
30. Powell, A. A. *et al.* Effectiveness of BNT162b2 against COVID-19 in adolescents. *Lancet Infect. Dis.* **22**, 581–583 (2022).
31. Han, S. *et al.* Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity. *Nat. Commun.* **12**, 4673 (2021).
32. Halloran, M. E., Longini, I. M. & Struchiner, C. J. *Design and Analysis of Vaccine Studies*. (Springer, 2010). doi:10.1007/978-0-387-68636-3.
33. Lewnard, J. A., Tedijanto, C., Cowling, B. J. & Lipsitch, M. Measurement of Vaccine Direct Effects Under the Test-Negative Design. *Am. J. Epidemiol.* **187**, 2686–2697 (2018).

34. Wu, J. T., Riley, S. & Leung, G. M. Spatial considerations for the allocation of pre-pandemic influenza vaccination in the United States. *Proc. R. Soc. B Biol. Sci.* **274**, 2811–2817 (2007).
35. Brooks-Pollock, E. *et al.* High COVID-19 transmission potential associated with re-opening universities can be mitigated with layered interventions. *Nat. Commun.* **12**, 5017 (2021).
36. Zhang, Y., Mayorga, M. E., Ivy, J., Hassmiller Lich, K. & Swann, J. L. Modeling the Impact of Nonpharmaceutical Interventions on COVID-19 Transmission in K-12 Schools. *MDM Policy Pract.* **7**, 23814683221140864 (2022).
37. Bowen, J. E. *et al.* Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. *Science* **377**, 890–894 (2022).
38. Accorsi, E. K. *et al.* Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA* (2022) doi:10.1001/jama.2022.0470.
39. Chen, J., Wang, R., Gilby, N. B. & Wei, G.-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. *J. Chem. Inf. Model.* **62**, 412–422 (2022).
40. Bobrovitz, N. *et al.* Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. *Lancet Infect. Dis.* **23**, 556–567 (2023).
41. Chemaitelly, H. *et al.* Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. *Lancet Microbe* **3**, e944–e955 (2022).
42. Murugesan, M. *et al.* Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India. *PLOS ONE* **17**, e0268797 (2022).

43. Jones, J. M. *et al.* Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021. *JAMA* **328**, 298–301 (2022).
44. Centers for Disease Control and Prevention (CDC). *2020-2021 Nationwide Blood Donor Seroprevalence Survey | Connecticut*. <https://covid19serohub.nih.gov/studies/S-1f88deea-873f-4b2a-8ec0-33041516e86c> (2021).
45. Tan, S. T. *et al.* Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. *Nat. Med.* 1–8 (2023) doi:10.1038/s41591-022-02138-x.
46. Contact Tracing for COVID-19. *Centers for Disease Control and Prevention* <https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/contact-tracing.html> (2022).
47. Poopalasingam, N. *et al.* Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals. *J. Clin. Virol.* **148**, 105119 (2022).
48. Lind, M. L. *et al.* Testing Frequency Matters: An Evaluation of the Diagnostic Performance of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Rapid Antigen Test in US Correctional Facilities. *Clin. Infect. Dis.* ciac450 (2022) doi:10.1093/cid/ciac450.
49. Connecticut Department of Correction. Health Information and Advisories. *CT.gov - Connecticut's Official State Website* <https://portal.ct.gov/DOC/Common-Elements/Common-Elements/Health-Information-and-Advisories> (2023).
50. Lind, M. L. *et al.* Covid-19 Vaccine Acceptance Among People Incarcerated in Connecticut State Jails. 2022.05.19.22275339 Preprint at <https://doi.org/10.1101/2022.05.19.22275339> (2022).

51. Lind, M. L. Evidence of Leaky Protection Following COVID-19 Vaccination and SARS-CoV-2 Infection in an Incarcerated Population. (2023) doi:600233692.

**Acknowledgements:** We are grateful to the individuals who provided the information for the analyses and thank the staff of the Connecticut Department of Corrections for their efforts in the response to the COVID-19 pandemic and in collecting data for the study. We also thank Ryan Borg and Dava Flowers-Poole for their assistance in the coordination of the study. This work was supported by a contract from the Connecticut Department of Public Health (Emerging Infections Program 2021-0071 to A.I.K.), the Raj and Indra Nooyi Professorship (to A.I.K.), and the Merck Investigator Studies Program (to W.L.S. and A.I.K.). The funders did not have a role in the design or implementation of the study nor the decision to publish the study. The study and its findings are the responsibility of the authors and do not reflect the views of the Connecticut Department of Correction.

**Author Contributions Statement:** MLL and AIK have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MLL, AIK, RPR, and BSK conceived the study. The data was collected and processed by MLL, MD, AJH, ML, BSK, and RPR. MLL, MD, MDTH, DATC, RT, and SL performed the analysis. MLL, AIK, BSK, MDTH, DATC, JRA, IY, SBO, WLS, and RR drafted the manuscript. All authors provided critical review of the results and contributed to manuscript revision. AJH, ML, BSK, RPR, and AIK supplied administrative, technical, and material support. Supervision was provided by BSK, RPR, DATC, and AIK.

**Ethics declarations:**

Competing Interests Statement

A.I.K is as an expert panel member for Reckitt Global Hygiene Institute, and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals and has received grants related to COVID-19 research outside the scope of the proposed work from Regeneron Pharmaceuticals and Tata Medical and Diagnostics. W.L.S. was an investigator for a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to Hugo Health, a personal health information platform, and co-founder of Refactor Health, an AI-augmented data management platform for healthcare; and has received grants related to COVID-19 research outside the scope of the proposed work from Regeneron Pharmaceutical. Other authors declare no conflict of interest.



## Tables

Table 1: Characteristics of Residents with and without Documented Exposure to SARS-CoV-2 Infected Residents

Characteristics	Delta Predominant Period (June 15, 2021 - December 12, 2022)			Omicron Predominant Period (December 13, 2021 - May 10, 2022)		
	Cell exposure events (N=264)	Cellblock exposure events (N=5616)	Events without documented exposures (N=17024)	Cell exposure events (N=702)	Cellblock exposure events (N=5980)	Events without documented exposures (N=13464)
Age (Median [Qr 1-3])	34 [27, 43]	36 [29, 46]	36 [29, 46]	37 [30, 46]	36 [28, 45]	36 [29, 46]
Gender Female (N [%])	38 (14.4%)	383 (6.8%)	1475 (8.7%)	111 (15.8%)	874 (14.6%)	1463 (10.9%)
Race & Ethnicity (N [%])						
Non-Hispanic Black	126 (47.7%)	2484 (44.2%)	7736 (45.4%)	318 (45.3%)	2644 (44.2%)	6052 (44.9%)
Non-Hispanic White	69 (26.1%)	1482 (26.4%)	4354 (25.6%)	210 (29.9%)	1753 (29.3%)	3987 (29.6%)
Other (Hispanic, American Indian, & Asian)	69 (26.1%)	1650 (29.4%)	4934 (29.0%)	174 (24.8%)	1583 (26.5%)	3425 (25.4%)
Duration of Incarceration (Median [QR 1-3]) <sup>a</sup>	181 [154, 181]	181 [181, 181]	181 [181, 181]	149 [149, 149]	149 [149, 149]	149 [149, 149]
Cell Size (Median [QR 1-3]) <sup>b</sup>	2 [2, 2]	2 [2, 2]	2 [2, 2]	2 [2, 2]	2 [2, 2]	2 [2, 2]
Cellblock Size (Median [QR 1-3]) <sup>b</sup>	75 [56, 129]	107 [69, 155]	88 [65, 140]	82 [61, 104]	89 [67, 133]	89 [65, 120]
History of Prior Infection (N [%]) <sup>c</sup>	85 (32.2%)	2180 (38.8%)	6522 (38.3%)	254 (36.2%)	2606 (43.6%)	6329 (47.0%)
History of Vaccination (N [%]) <sup>c</sup>	109 (41.3%)	3013 (53.7%)	9141 (53.7%)	379 (54.0%)	3401 (56.9%)	7693 (57.1%)
History of Hybrid Immunity (N [%]) <sup>c</sup>	45 (17.0%)	1379 (24.6%)	4289 (25.2%)	168 (23.9%)	1729 (28.9%)	4095 (30.4%)
Follow-up Time (Median [Qr 1-3])	14 [14, 14]	14 [14, 14]	14 [4, 14]	14 [14, 14]	14 [14, 14]	9 [2, 14]

<sup>a</sup> Duration of incarceration (in days) including the SARS-CoV-2 exposure event type

<sup>b</sup> Number of cellmates or unit-mates at the time of the exposure event that resulted in study inclusion

<sup>c</sup> History of prior infection defined as a record of prior infection (defined as prior infection defined as the record of a positive SARS-CoV-2 test (rapid antigen or RT-PCR) at least 90 days prior to follow-up start date); history of vaccination defined as receipt of at least one vaccine dose as of the start of follow-up; hybrid immunity defined as a recorded prior infection and vaccination as of the start of the study period

## Figure Legends

Figure 1: Vaccination coverage, SARS-CoV-2 testing, Proportion of Residents Tested, and SARS-CoV-2 infections in the Connecticut Correctional Facility system between June 15, 2021, and May 10, 2022

The (A) vaccination coverage (red: boosted, light blue: primary vaccination, green: partially vaccinated, navy: unvaccinated), (B) number of SARS-CoV-2 tests conducted as part of mass screening (light blue), contact tracing in the absence of recorded symptoms (navy), intake/transfer testing in the absence of recorded symptoms (grey/blue), other testing in the absence of recorded symptoms (brown), and testing in the presence of recorded symptoms (symptoms data not available for mass screening [PCR] testing; red), (C) proportion of residents tested during a rolling 14-day period among all residents (red) and residents with cell exposure events (green), cellblock exposure events (brown), and no documented exposure events (navy), (D) number of SARS-CoV-2 infections detected as part of mass screening (light blue), contact tracing in the absence of recorded symptoms (navy), intake/transfer testing in the absence of recorded symptoms (grey/blue), other testing in the absence of recorded symptoms (brown), and testing in the presence of recorded symptoms (red) among people who resided in Connecticut Department of Correction Facility cells between June 15, 2021, and May 10, 2022. During the study period, RT-PCR tests were collected for mass testing and rapid antigen tests were collected for the following primary reasons: intakes/transfer, contact tracing, symptom presence, and employment. Infections were defined as a positive test (RT-PCR or rapid antigen test) collected in the absence of a positive test in the last 90 days. Residents were classified as having a cell exposure event on the day their cellmate tested positive, having a cellblock exposure event the day a resident of their cellblock but not cell tested positive, and having an event without documented exposures if no one in their cellblock tested positive on a given day.

Figure 2: Selection of the rolling matched cohort of residents according to their facility exposures

Flowchart showing how people incarcerated within Connecticut Department of Correction facilities and who resided in cells between June 15, 2021, and December 12, 2021 (Delta Predominant Period [A]) and December 13, 2021, and May 10, 2022 (Omicron Predominant Period [B]), were included in the analysis. Residents were classified as having a cell exposure event (green) on the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure (navy) if no one in their cellblock tested positive on a given day. Cell exposure events that occurred within 14 days following a prior cell exposure event were excluded. Cellblock exposure events and events without documented exposures that occurred in the 14 days following a cellblock or cell exposure event were excluded. <sup>a</sup>To prevent the inclusion of multiple events without documented exposures from the same person during a 14-day period, we randomly selected incarceration events without documented exposures and excluded all others within the prior or following 14 days. <sup>b</sup>We defined infections as a positive RT-PCR or rapid antigen test during the 14 days of follow-up.

Figure 3: Association between documented exposure and SARS-CoV-2 infection risk among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022

Forest plot depicting the association between documented close exposure to a SARS-CoV-2 infected resident and the risk of subsequent SARS-CoV-2 infection. Residents were classified

as having a cell exposure event (green) on the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure if no one in their cellblock tested positive on a given day. Cell exposure events that occurred within 14 days following a prior cell exposure event were excluded. Cellblock exposure events and events without documented exposures that occurred in the 14 days following a cellblock or cell exposure event were excluded. Facility exposures were stratified by periods of variant predominance (Delta [A]: June 15, 2021 – December 12, 2021; Omicron [B]: December 13, 2021 – May 10, 2022). The associations were estimated using a Cox Proportional Hazard Model stratified by facility and with robust standard errors. The model was adjusted for age, calendar date, race, room and cellblock size, vaccination, and prior infection status of the susceptible person. Boxes indicate estimated hazard ratio (HR) point values and whiskers indicate 95% confidence intervals (Delta Period: n = 22,904 facility events; Omicron Period: n = 20,146 facility events). Unadjusted results presented in Supplement Table 3.

Figure 4: Effectiveness of prior infection vaccination, and hybrid immunity on SARS-CoV-2 infection among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022, by documented exposure status

Forest plot depicting the association between prior infection, vaccination, and hybrid immunity and the risk of SARS-CoV-2 infection by facility exposure type. Residents were classified as having a cell exposure event (green) the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure (navy) if no one in their cellblock tested positive. Cell exposure events that occurred within 14 days following a prior cell exposure event were excluded. Cellblock exposure events and events without documented exposure that occurred in the 14 days following a cellblock or cell exposure event were excluded. Associations were examined using Cox Proportional Hazard Models stratified by cellblock with robust standard errors. Each model was adjusted for age, date of exposure, race, room size, and model (a) was adjusted for vaccination status and model (b) was adjusted for prior infection status. Model (c) was limited to residents with hybrid immunity or residents without a record of prior infection or vaccination. Prior infection was defined as a recorded positive SARS-CoV-2 test  $\geq 90$  days before the event and vaccination was defined as the receipt of  $\geq 1$  dose before the event. Hybrid immunity was defined as a record of both a prior infection and  $\geq 1$  vaccine dose. Boxes indicate estimated hazard ratio (HR) point values and whiskers indicate 95% confidence intervals (Delta: n = 17,024 no exposure events, 5,616 cellblock exposure events, 264 cell exposure events; Omicron: n = 13,464 no exposure events, 5,980 cellblock exposure events, 702 cell exposure events). Ratio of HRs refer to the p-value comparing the HR following cellblock or cell exposure events to the HR following events without documented exposures, estimated using two-sided z-tests. No multiple testing adjustment was performed. Unadjusted results in Supplement Table 7.

Figure 5: Effectiveness of prior infection and vaccination status of index cases on SARS-CoV-2 transmissibility among of residents of Connecticut Department of Correction facility between June 15, 2021, and May 10, 2022, by documented SARS-CoV-2 exposure status

Forest plot depicting the association between vaccination and prior infection and the risk of subsequent SARS-CoV-2 infection by documented SARS-CoV-2 exposure status. Residents were classified as having a cell exposure event (green) on the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure if no one in their cellblock tested positive on a given day. Cell exposure events that occurred within 14 days following a prior cell

exposure event were excluded. Cellblock exposure events and events without documented exposures that occurred in the 14 days following a cellblock or cell exposure event were excluded. Residents were classified as being vaccinated if they had received at least one vaccine dose. Associations were examined using Cox Proportional Hazard Models stratified by housing cellblock with robust standard errors. The models were adjusted for (a) age, date of exposure, race, room size, vaccination and prior infection status of the susceptible resident, and vaccinated status of the index case (limited to exposed residents), (b) age, date of exposure, race, room size, vaccination and prior infection status of the susceptible resident, and prior infection status of the index case (limited to exposed residents). Prior infections were defined as a recorded positive SARS-CoV-2 test at least 90 days prior to the event and vaccination was defined as the receipt of at least one dose prior to the event. Boxes indicate estimated hazard ratio (HR) point values and whiskers indicate 95% confidence intervals (Delta: n = 4,407 cellblock exposure events, 127 cell exposure events; Omicron: n = 3,831 cellblock exposure events, 250 cell exposure events).

## Figures

Figure 1: *Vaccination coverage, SARS-CoV-2 testing, Proportion of Residents Tested, and SARS-CoV-2 infections in the Connecticut Correctional Facility system between June 15, 2021, and May 10, 2022*




Figure 2: Selection of the rolling matched cohort of residents according to their facility exposures




Figure 3: Association between documented exposure and SARS-CoV-2 infection risk among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022

**A. Delta Period**

Type of Facility Exposure	Facility Infections	Facility Exposures	HR (95% CI)
No Exposure	122	17024	
Cellblock Exposure	233	5616	2.67 (1.84, 3.88)
Cell Exposure	53	264	9.70 (6.29, 14.96)

**B. Omicron Period**

Type of Facility Exposure	Facility Infections	Facility Exposures	HR (95% CI)
No Exposure	167	13464	
Cellblock Exposure	502	5980	3.34 (2.22, 5.00)
Cell Exposure	109	702	4.73 (3.05, 7.36)

Figure 4: Effectiveness of prior infection vaccination, and hybrid immunity on SARS-CoV-2 infection among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022, by documented exposure status




Figure 5: Effectiveness of prior infection and vaccination status of index cases on SARS-CoV-2 transmissibility among of residents of Connecticut Department of Correction facility between June 15, 2021, and May 10, 2022, by documented SARS-CoV-2 exposure status

